PBH:NYSEPrestige Consumer Healthcare Inc. Analysis

The stock is trading at $46.6, well under its 20‑day (≈$54), 50‑day (≈$57) and 200‑day (≈$62) simple moving averages, signaling a bearish technical backdrop. Momentum indicators reinforce this view, with the RSI sitting at 27 points—deeply oversold—and the MACD line lingering below its signal, producing a bearish histogram. Nevertheless, the price remains comfortably above the calculated support level of $42.6, and volume has been trending upward, suggesting some buying interest. Volatility is elevated at roughly 45 % over the past 30 days, while the beta of 0.36 indicates the stock moves less than the broader market, tempering systematic risk.
On the fundamentals side, total revenue for FY 2026 slipped 5 % to $1.09 billion, reflecting modest top‑line weakness. The company still posts healthy profitability, with a gross margin of 56 % and an operating margin of 27 %, delivering a trailing EPS of $3.91 and a forward EPS of $4.85. Valuation appears attractive relative to peers, as the current P/E of 11.9 is less than half the industry average of 26.9, though the discounted cash‑flow model estimates a fair value near $32, implying the market price is above intrinsic. The balance sheet is leveraged, carrying $1.05 billion of debt against $64 million of cash, yielding a debt‑to‑equity of 55 % and a modest ROE of 10 %. Analysts remain optimistic, with a median price target of $72 and an implied upside of roughly 49 %, even as Oppenheimer trimmed its recommendation to “perform.” The latest earnings report missed consensus, posting adjusted EPS of $1.23 versus the $1.39 estimate, and highlighted supply constraints in the Clear Eyes line, though management projects FY 2027 revenue of $1.1‑$1.12 billion and expects back‑half growth. In this mix of bearish technical signals, solid cash‑flow generation, and a sizable upside thesis, the stock warrants a cautious but potentially rewarding stance. Investors should monitor the support level, upcoming guidance, and any improvement in earnings momentum before scaling exposure.